private equity
private equity on Beyond Market Intelligence: a running collection of 2 stories we have gathered and hand-picked because they are worth your time. Every post here touches on private equity in some way — the news, the analysis, the deep dives, and the occasional surprise find. Acme AI is the next-generation, AI-powered spreadsheet platform built to replace Excel and redefine how analysts, data scientists, and enterprise teams work with data. New stories are added to this page as we find them, so check back if you want to keep up with what is happening around private equity, or subscribe to the RSS feed to get them as soon as they are published. Browse the collection below, or head back to the homepage to see everything Beyond Market Intelligence is covering right now.
Colossal Biosciences reportedly in talks to raise new capital at $20B–$30B valuation
Colossal Biosciences, the ambitious startup focused on de-extinction, is reportedly exploring a significant new capital raise. Sources indicate the company is targeting a valuation between $20 billion and $30 billion – a potential doubling or tripling of its previous assessment. This move underscores the growing investor interest in the intersection of biotechnology and synthetic biology. For those tracking the broader AI investment landscape, the recent $15 million raise by inference startup Infinity offers further insight into current market dynamics.
Nuclear startup Valar Atomics in talks to raise new funding at $6B valuation
Valar Atomics, a nuclear fission startup, is reportedly in discussions to secure new funding at a substantial $6 billion valuation, signaling a continued shift towards intricate, multi-stage investment rounds. This approach often obscures initial entry prices, reflecting a complex landscape for emerging companies. The potential funding underscores growing investor interest in advanced nuclear technologies. For founders navigating similar challenges, consider the strategies discussed in "No product? No problem. This Disrupt 2026 session…" for securing early-stage capital.